Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07243015 · ClinicalTrials.gov registry record
Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers
A clinical trial of Gastric Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT07243015 is a study of Gastric Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 500 participants, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07243015, a study of Gastric Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST small RNA-seq or array
- DIAGNOSTIC_TEST ENLIGHT Assay
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07243015
The ClinicalTrials.gov registry entry for NCT07243015 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (58% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which small RNA-seq or array is the first listed.
NCT07243015 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07243015 about?
NCT07243015 is a clinical study titled "Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers". Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific...
What is the current status of trial NCT07243015?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-01-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07243015 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT07243015?
The interventions under investigation include: small RNA-seq or array (DIAGNOSTIC_TEST), ENLIGHT Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07243015?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07243015 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.